In osteopetrosis, osteoclast dysfunction can lead to deafness, blindness, bone marrow failure and death. Hematopoietic cell transplantation (HCT) is currently the only curative treatment, but outcome remains disappointing. Although a rapid progression towards HCT is detrimental to prevent further progress of disease manifestations, 70 percent of cases lack an HLA-matched sibling and require alternative stem cell sources. We present two cases of osteopetrosis that successfully received an HCT with haploidentical TcRαβ-depleted cells from one of the parents. These cases showed no further disease progression, had restoration of functional osteoclasts and illustrate this approach to enable prompt HCT with ready available parental donors and rapid and sustained hematological, including osteoclast, recovery. ! 3!
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INTRODUCTION
Osteopetrosis (OP) is a genetic disorder characterized by improper bone resorption (1) that in most cases is caused by dysfunctional, hematopoietic stem cell (HSC)-derived osteoclasts. Most clinical phenotypes require hematopoietic cell transplantation (HCT) as the only current curative treatment. (1, 2) In malign infantile OP (MIOP), performing HCT without delay is required to restore rapid osteoclast function to prevent progression of irreversible damage, including bone marrow failure, blindness and deafness. (1) Also in more slowly progressing OP cases terminal bone marrow failure often urges for HCT. (1) Still, the outcome of HCT in OP remains disappointing. The overall survival, at best, is 60-65% (1, 3, 4) in all OP cases and below 50% for OP cases who do not have an HLA-identical sibling donor (approximately 70% of cases). Graft failure is the most common cause of death. (3) Autosomal recessive OP is overrepresented in ethnic groups with high parental consanguinity, (1) of which many have a low coverage within the bone marrow donor registries. Therefor alternative donors are to be considered when no HLA-identical healthy sibling is available. Moreover, even if a register donor is identified, a donor search is time consuming and justifies the use of alternative, ready available donors. As such, cord blood transplantation has been used in the context of OP but was associated with higher transplant-related morbidity and mortality. (3, 5) HCT in MIOP using a parental haploidentical donor is seemingly attractive because the parents typically are readily available. A number of reports have described haploidentical transplantation (Haplo-HCT) using CD34-enriched mobilized peripheral blood stem cells (PBSC). (6) (7) (8) (9) However, complications such as delayed hematological and immunological recovery, graft rejection, and, or, the need for a stem cell boost were frequently observed.
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Generally in Haplo-HCT, the use of a T cell receptor alpha beta (TcRαβ)depleted graft, as opposed to CD34 enrichment, confers rapid hematological and immunological reconstitution, (10, 11) most likely because of the presence of highly proliferative, CD34-negative progenitor cells alongside the HSC in the graft. Also, the high numbers of TcRγδ cells, NK cells and monocytes in the TcRαβ-depleted graft may act to facilitate engraftment. The use of a TcRαβ-depleted graft has already been reported as successful in three OP cases, (12) but not in the context of a haploidentical donor. Together, we hypothesize that TcRαβ-depleted Haplo-HCT is an attractive approach to i) perform HCT without delay, ii) induce a fast recovery of osteoclast (15 mg/kg). Since the risk of graft rejection seems to be correlated with the intensity of the conditioning regimen, he received a busulfan dose typically recommended for malignant diseases, although data addressing the optimal busulfan dose for OP cases is scarce. There is some evidence that replacing cyclophosphamide by fludarabine may increase survival, probably by reducing the risk of pulmonary and hepatic venoocclusive disease (VOD). (14) Still, VOD was observed among cases conditioned with a combination of busulfan and fludarabine an as our cases received a high target busulfan AUC it was decided to give defibrotide as VOD prophylaxis, 25mg/kg/d from start of conditioning therapy until day +30. Maternal G-CSF-mobilized PBSC were harvested and TcRαβ+ cells were depleted from the graft (CliniMACS). The case was transplanted with a single graft including 10.9×10 8 mixed T cell chimerism), the case received immunosuppression with cyclosporine A and steroids, which was stopped at day +159 with complete donor chimerism of myeloid cells and stable mixed chimerism (21% autologous) of CD3+ cells. As previously described (15) and as a consequence of potent allogeneic osteoclast recovery, the case developed hypercalcaemia that required regular treatment with the RANKL-inhibitor denosumab at least until the last day of follow-up, day +308, of which the first 225 days are illustrated in Figure 2C . The case showed normalization of the phenotypic facial characteristics in the absence of graft-versus-host disease.
DISCUSSION
We present here two cases with osteoclast-rich OP (Figures 1B and 2B ) that, as opposed to osteoclast-poor OP, can profit from HCT as curative treatment modality. Both cases successfully received a parental haploidentical TcRαβ-depleted transplantation, following full myeloablative conditioning and high-dose serotherapy with ATG. Both cases showed transient mixed chimerism before converting to 100% donor chimerism. Importantly, neither case rejected the graft or required a stem cell boost due to graft failure, as often occurs following HCT in OP. (1, 3) Also, despite the intensive conditioning regimens no VOD or severe viral infections were observed.
The first case represents a MIOP population, who require rapid HCT and recovery of osteoclast function to stop further progression of the disease. The approach presented here illustrates the feasibility of TcRαβ-depleted Haplo-HCT in such a case, with HCT and hematopoietic recovery both commencing within only a few weeks of the OP diagnosis. In support of this early intervention, no further phenotypic progression of the disease was observed. The second case illustrates that TcRαβ-depleted Haplo-HCT in cases with slower disease progression but who ultimately progress to bone ! 8! marrow failure is also an effective means of restoring osteoclast function, when an HLA-identical sibling or unrelated donor is not available. We speculate that the preservation of large numbers of CD34-negative myeloid progenitors (the direct ancestor of the osteoclast lineage) contained in the graft following TcRαβ-depletion, as opposed to a CD34 enrichment that depletes most of the CD34-negative cell fraction, allows for the desired and rapid osteoclast recovery in OP cases.
Overall, we conclude that Haplo-HCT using TcRαβ-depleted cells is an encouraging approach in malignant infantile OP that enables i) prompt HCT with immediate availability of a parental donor and ii) rapid and sustained hematological recovery. Both cases show objective signs of osteoclast recovery, with normalisation of radio imaging in case one ( Figure 1C ), and hypercalcaemia in case two ( Figure   2C 
